Cargando la página…
World Journal of Pharmaceutical Research
Por Pooja T.1*, Samiya Eram1, Sindhu L.1, C. M. Chandana1, Abhishek C. Pasarad2.
Contenido en inglés
This study explores the neuroprotective potential of sitagliptin, an anti-diabetic drug, in managing Alzheimer's disease (AD) symptoms in a streptozotocin (STZ)-induced rat model.
Ward reúne estos artículos en la misma app que tus tarjetas y preguntas. Una cuenta gratis para Ward, Suture, Osler y Prognia.
This research aimed to assess whether sitagliptin could improve cognitive function and reduce anxiety by modulating acetylcholinesterase (AChE) activity.
Rats were divided into five groups: a control, a negative control with only STZ, a standard treatment group with STZ and Rivastigmine, and low- and high-dose sitagliptin groups (5 mg/kg and 10 mg/kg, respectively). Cognitive performance was evaluated using the elevated plus-maze test, which measures spatial memory and anxiety-like behaviors.
It was showed that both low and high doses of sitagliptin led to significant behavioral improvements, with the high dose producing effects comparable to Rivastigmine, the standard AD treatment. Notably, sitagliptin administration reduced AChE activity, correlating with observed cognitive and anxiety-related improvements, suggesting its action may involve modulation of cholinergic pathways. These findings support sitagliptin's potential as an adjunct or alternative treatment for AD, especially considering its dose-dependent effects.
The study underscores the need for further research into sitagliptin’s broader neuroprotective mechanisms, particularly its impact on AD biomarkers such as amyloid-beta and tau proteins. This research provides promising insights into the potential repositioning of sitagliptin for neurodegenerative disease management, highlighting its prospective benefits in AD treatment.
Publicado en World Journal of Pharmaceutical Research. El resumen se muestra tal como se publicó y sigue siendo obra de sus autores; lee el artículo completo en la fuente.
Prognia recoge este artículo como referencia y para la formación. No es consejo médico. Lee siempre el original y sigue las guías vigentes y los protocolos locales antes de actuar.
